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Background—Data on causes of death due to respiratory illness in Africa are limited.
Methods—From January to April 2013, 28 African countries were invited to participate in a 
review of severe acute respiratory illness (SARI)–associated deaths identified from influenza 
surveillance during 2009–2012.
Results—Twenty-three countries (82%) responded, 11 (48%) collect mortality data, and 8 
provided data. Data were collected from 37 714 SARI cases, and 3091 (8.2%; range by country, 
5.1%–25.9%) tested positive for influenza virus. There were 1073 deaths (2.8%; range by country, 
0.1%–5.3%) reported, among which influenza virus was detected in 57 (5.3%). Case-fatality 
proportion (CFP) was higher among countries with systematic death reporting than among those 
with sporadic reporting. The influenza-associated CFP was 1.8% (57 of 3091), compared with 
2.9% (1016 of 34 623) for influenza virus–negative cases (P < .001). Among 834 deaths (77.7%) 
tested for other respiratory pathogens, rhinovirus (107 [12.8%]), adenovirus (64 [6.0%]), 
respiratory syncytial virus (60 [5.6%]), and Streptococcus pneumoniae (57 [5.3%]) were most 
commonly identified. Among 1073 deaths, 402 (37.5%) involved people aged 0–4 years, 462 
(43.1%) involved people aged 5–49 years, and 209 (19.5%) involved people aged ≥50 years.
Conclusions—Few African countries systematically collect data on outcomes of people 
hospitalized with respiratory illness. Stronger surveillance for deaths due to respiratory illness may 
identify risk groups for targeted vaccine use and other prevention strategies.
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Respiratory disease remains a major cause of mortality globally. Influenza virus infections 
alone may cause an estimated 250 000–500 000 deaths each year [1]. However, the burden 
of influenza-associated mortality in different regions and settings is not well understood. 
Available data suggest both the respiratory disease– and influenza-associated mortality may 
be increased in low-income settings such as sub-Saharan Africa [2–5]. In South Africa, 
influenza-associated age-standardized mortality rates among individuals aged ≥65 years, 
among whom the human immunodeficiency virus (HIV) prevalence is very low, were 2–4 
times higher than that among individuals of the same age in the United States [6]. Severe 
influenza outbreaks in Madagascar and Democratic Republic of the Congo (DRC) in 2002 
were also associated with high case-fatality proportions (CFPs) [7, 8]. These mortality data 
are supported by surveillance data from 14 African countries during 2006–2010 that found 
that 8.9% of hospitalizations that met the case definition for severe acute respiratory illness 
(SARI) were associated with influenza virus infection [9], suggesting that influenza is an 
important cause of severe respiratory disease in Africa.
Globally, the 2009 influenza A(H1N1) pandemic was estimated to result in nearly 300 000 
deaths in the first 12 months after virus emergence. More than half of these deaths may have 
occurred in Southeast Asia and Africa [4]. In Madagascar, influenza-attributable mortality 
was 20% higher than estimates of mortality attributable to seasonal influenza from previous 
years in the capital city Antananarivo [10], and early data from South Africa identified a 
high proportion of pregnant women, as well as individuals with HIV infection and 
tuberculosis among fatal cases [11]. Likewise, a global pooled analysis of influenza-
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associated hospitalizations and deaths during the 2009 pandemic found pregnancy to be 
associated with a relative risk of hospitalization of 6.8 and a relative risk of death of 1.9. 
While HIV infection and active tuberculosis were not assessed individually by the global 
pooled analysis, among patients hospitalized with influenza immunocompromise was 
associated with a relative risk of death of 27.7 and chronic respiratory disease was associated 
with a relative risk of death of 7.8 [12]. Using a different modeling method, another study 
estimated that a much lower proportion of pandemic mortality occurred in Africa [13]. 
Therefore, respiratory disease–associated mortality data from multiple countries in sub-
Saharan Africa are essential to better understanding the impact of pandemic and seasonal 
influenza.
The high prevalence of comorbid conditions, including HIV infection, tuberculosis, and 
pregnancy, may contribute to increased disease severity and mortality from influenza in 
Africa [14]. Limited access to health care may also increase mortality from respiratory 
diseases in Africa. HIV infection, Mycobacterium tuberculosis coinfection, underlying 
medical conditions, pneumococcal coinfection, and intensive care unit admission were 
associated with increased mortality among influenza virus–positive patients with SARI in 
South Africa [2]. South Africa also estimated that influenza-associated mortality rates were 
3.8 times greater (95% confidence interval [CI], 2.2–6.6) in adults aged 25–54 years, the age 
group with the highest HIV seroprevalence, than in adults aged ≥65 years [15].
Specific data on rates and risk groups for influenza-associated mortality are needed to help 
inform target groups for vaccine policy and to help inform allocation of resources in a 
pandemic. Hospital-based influenza surveillance has increased dramatically in Africa in the 
last decade [9], and we assessed whether the current systems could provide insights into 
seasonal influenza–associated mortality among persons hospitalized for respiratory disease 
in Africa, as well as data on other etiologies of respiratory disease–associated mortality in 
sub-Saharan Africa.
METHODS
Between January to April 2013, we sent a standard data template to representatives of 28 
(59%) of 46 World Health Organization (WHO) African Region Member States. These 
included all 24 countries who reported data to the WHO’s FluNet in 2012 and countries that 
we were aware were conducting systematic hospital-based SARI surveillance 
(Supplementary Table 1). We requested information on all SARI cases and SARI-associated 
deaths detected by surveillance during 2009–2012. SARI case definitions used by these 
countries were consistent with WHO recommendations for adults and children <5 years of 
age [16]; however, some countries used expanded case definitions to include 14 days of 
symptom duration and/or physician-diagnosed lower respiratory tract infection. WHO-
recommended case definitions were updated in 2011, and many countries have recently 
updated SARI case definitions to reflect these recommendations. The WHO’s current SARI 
case definition for all age groups is an acute respiratory infection with a subjective or 
measured temperature of ≥38°C and cough with onset in the last 10 days requiring 
hospitalization [17]. Variables collected in SARI surveillance included the number of 
subjects enrolled, the number of specimens tested for influenza virus by real-time reverse 
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transcription–polymerase chain reaction (rRT-PCR), influenza virus rRT-PCR test results, 
age, and outcome of hospitalization (discharge or death). We collected additional variables 
for SARI-associated deaths, including sex, pregnancy status, underlying medical conditions, 
and results of testing for other respiratory infections. Nasopharyngeal and oropharyngeal 
swab specimens or nasal aspirates were collected from enrolled SARI cases to test for 
influenza virus and other respiratory viruses. Except for Malawi, which conducts internal 
quality assurance, all countries providing data participate in the WHO’s External Quality 
Assurance Project for influenza diagnosis. Data on Streptococcus pneumoniae from Kenya, 
South Africa, and Madagascar were from blood culture or blood lytA PCR and are indicative 
of invasive disease [18, 19]. HIV infection, tuberculosis, and other comorbid conditions 
were reported according to local diagnostic and surveillance practices and were not 
independently verified.
Data were analyzed using SAS 9.3 (SAS Institute, Cary, North Carolina). The Wilcoxon 
rank sum test was used to assess statistical significance of differences in nonparametric 
variables. The Pearson χ2 test was used to test for associations between categorical variables 
and influenza virus infection among SARI-associated deaths.
RESULTS
Representatives from 23 of 28 countries (82%) provided information about their country’s 
SARI surveillance. Of these 23 countries, 11 (48%) did not collect outcome data on persons 
hospitalized for SARI, 9 (38%) collected SARI-associated mortality data systematically 
either prospectively or retrospectively, 2 (8%) received reports of SARI-associated deaths 
from sentinel sites but not systematically, and 1 (4%) had <1 year of surveillance data. Of 
the 11 countries that collected mortality data either systematically or via sentinel site reports, 
the following 8 completed the standard template for this analysis: DRC, Kenya, Madagascar, 
Malawi, Rwanda, South Africa, Tanzania, and Uganda. Of these, DRC, Tanzania, and 
Uganda receive reports of SARI-associated deaths from sentinel sites but did not collect 
these data systematically; Rwanda conducted a retrospective review of medical charts and 
registers to identify SARI-associated deaths; and the remaining countries (Kenya, 
Madagascar, Malawi, and South Africa) collect SARI outcome data (including mortality) 
prospectively from the time of enrollment in SARI surveillance to the time of hospital 
discharge or death. Community deaths following discharge were not reported by any 
country. SARI surveillance was primarily conducted in pediatric and/or adult medical wards 
at surveillance hospitals, and surveillance practices varied by country in terms of the number 
of cases enrolled per day or the days of enrollment per week.
During 2009–2012, the 8 countries that provided data on SARI-associated deaths enrolled 
40 355 subjects, of whom 1222 (3.0%) died during hospitalization. Complete data on 
influenza virus testing and age were available for 37 714 SARI cases (93.5%). Among these 
cases, 1073 deaths were reported (SARI CFP, 2.8%), ranging widely by country, from 0.1% 
in DRC to 5.5% in Madagascar. Among the 37 714 SARI cases tested for influenza virus, 
3091 (8.2%) tested positive for influenza virus, ranging from 5.1% in Tanzania to 25.9% in 
Madagascar (Table 1).
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Of 1073 SARI cases who died during hospitalization and were tested for influenza virus, 57 
(5.3%) tested positive, for an overall influenza-associated CFP of 1.8% (57 of 3091), 
compared with 2.9% (1016 of 34 623) among influenza virus–negative SARI cases (P < .
001). The influenza-associated CFPs ranged from 0 in Malawi, Tanzania, and Uganda to 
3.6% in Madagascar. Countries with systematic death reporting had higher all-cause and 
influenza-associated CFPs than countries with sporadic reporting. Of the 1073 reported 
deaths, 402 (37.5%) were among children aged 0–4 years, 462 (43.1%) were among children 
and adults aged 5–49 years, and 209 (19.5%) were among adults aged ≥50 years (Table 1).
Among the 57 influenza-associated deaths, 19 (33.3%) were among children aged 0–4 years, 
20 (35.1%) were among adults aged 18–49 years, and the remaining 18 (31.5%) were among 
adults aged ≥50 years (Table 1). The median age among influenza-associated deaths was 32 
years (interquartile range [IQR], 1–56 years), compared with 28 years (IQR, 1–45 years) 
among SARI-associated deaths without influenza virus infection (P = .05). The influenza-
associated CFP varied by age group and was highest among adults aged ≥65 years (8.2%) 
and lowest among children aged 5–17 years (0%; P < .001). Persons aged ≥65 years 
accounted for just 2.5% of SARI cases but 7.2% of SARI-associated deaths and 14.0% of 
influenza-associated deaths due to SARI.
Among 1073 SARI-associated deaths, data on underlying medical conditions were 
incomplete (Table 2). Despite the limited availability of data, 532 deaths (49.6%) were 
reported to have an underlying medical condition (including HIV infection and M. 
tuberculosis infection). Among 1073 deaths, HIV status was reported for 580 (54.1%), and, 
of these, 419 (72.2%) were infected with HIV. Thirty-three of 57 influenza virus–positive 
deaths (57.9%) had HIV status information, and, of these, 23 (69.7%) were HIV infected. A 
total of 547 of 1016 influenza virus–negative deaths (53.8%) had HIV status reported, and 
396 (72.4%) were HIV infected (P = .74). Among the 661 deaths (61.6%) with data, 
tuberculosis was reported for 103 (15.6%), and there was no difference in the prevalence of 
tuberculosis among influenza virus–positive and influenza virus–negative deaths (P = .34). 
Information on asthma was available for 1056 SARI-associated deaths (98.4%) but was 
rarely identified in both influenza virus–positive (3.6%) and influenza virus–negative deaths 
(1.6%; P = .24). Information on other medical conditions was reported for 720 deaths 
(67.1%). Among children and adults with a reported underlying medical condition, HIV 
infection was most commonly reported among all ages (419 of 532 cases [78.8%]), followed 
by malnutrition (11 of 96 [11.5%]) and tuberculosis (8 of 96 [8.3%]) for children aged 0–4 
years and tuberculosis (95 of 436 [21.8%]) and diabetes (25 of 436 [5.7%]) for children and 
adults aged ≥5 years. Of the 245 deaths among women of childbearing age, pregnancy status 
was provided for 237 (96.7%), of whom 7 (3.0%) were pregnant at the time of death. None 
of the 7 pregnant women with SARI identified in routine surveillance who died were 
infected with influenza virus.
Among the 57 influenza-associated deaths, 9 (15.8%) were confirmed as involving influenza 
A(H1N1)pdm09 infection, 19 (33.3%) as involving influenza A(H3N2) infection, and 20 
(35.1%) as involving influenza B infection; nonsubtyped influenza A infection was detected 
in 9 (15.8%). There were no statistically significant differences in the distribution of deaths 
by influenza virus subtype by age group (P = .72).
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Other respiratory pathogens were identified by culture or PCR testing only in Kenya, 
Madagascar, and South Africa. Specimens from 834 deaths in these countries were tested for 
the presence of at least 1 other respiratory pathogen: 247 deaths (30%) involved children 
aged 0–4 years, and 587 (70%) involved persons aged ≥5 years. Among the 247 deaths in 
children aged 0–4 years tested for other pathogens, 145 (59%) tested positive for a 
respiratory pathogen, with influenza virus detected in 14 (6%) and ≥1 respiratory pathogen 
other than influenza virus detected in 131 (53%). Among those aged 0–4 years, the most 
commonly identified respiratory pathogens other than influenza virus were rhinovirus (35 
cases [14.2%]), respiratory syncytial virus (33 [13.4%]), and adenovirus (32 [13.0%]; Table 
3). Among deaths involving children aged 0–4 years, those testing negative for influenza 
virus were more likely to have another respiratory virus identified than those who tested 
positive for influenza virus (P = .014).
Among the 587 deaths in persons aged ≥5 years who were tested, 243 (41%) tested positive 
for a respiratory pathogen, with influenza virus detected in 37 (6%) and ≥1 respiratory 
pathogen other than influenza virus detected in 206 (35%). The most commonly identified 
respiratory pathogens other than influenza virus in this age group were rhinovirus (72 cases 
[12.3%]), S. pneumoniae (48 [8.2%]), and adenovirus (32 [5.5%]; Table 3).
DISCUSSION
Hospital-based surveillance for severe respiratory disease in Africa has expanded 
dramatically in the last decade, yet data on etiologies of mortality are very sparse. Our aim 
was to assess the capacity of SARI surveillance to collect mortality data and provide initial 
insights of the characteristics of SARI and influenza-confirmed deaths, rather than to 
accurately document the burden of influenza-associated mortality. We found that few 
countries that conduct influenza surveillance are systematically collecting data on outcomes 
of hospitalization, and available information on deaths is sparse and incomplete. Likewise, 
data on the presence of comorbidities were incomplete. We also found that pregnant women 
were underrepresented in SARI data from all countries. We found a wide range in CFPs for 
SARI and influenza across countries, which may reflect differences in case definitions, 
criteria for hospitalization, quality of hospital care, or quality of surveillance, including 
proper handling of biological specimens and ascertainment of deaths. Countries where 
deaths are reported from sites sporadically had lower CFPs than those that reported deaths 
systematically, suggesting that sporadic reporting may fail to capture a large number of 
SARI-associated deaths. Reports of hospitalizations and deaths from low-income and 
middle-income settings during the 2009 A(H1N1) pandemic include La Reunion (255 
hospitalizations and 6 deaths; CFP, 2.4%), Argentina (11 086 hospitalizations and 580 
deaths; CFP, 5.2%), and Chile (1585 hospitalizations and 134 deaths; CFP, 8.5%) [20]. The 
majority of published data on SARI CFPs from African countries is focused on children. A 
meta-analysis of 11 African studies in children aged 0–59 months found an average in-
hospital CFP of 3.9% (95% CI, 2.7%–5.5%) among children hospitalized with acute lower 
respiratory tract infections [3]. Comparison with CFP estimates among respiratory disease–
associated hospitalizations from the region suggests incomplete death reporting in this 
analysis.
McMorrow et al. Page 6













Despite the incomplete data, we were able to draw some important conclusions. First, in-
hospital respiratory mortality and influenza-associated mortality occur predominantly in 
very young individuals and those 18–49 years. Second, a viral pathogen could be identified 
in 38% of deaths tested for influenza virus and other respiratory pathogens. In particular, our 
data highlight the role that respiratory syncytial virus and adenovirus may play in respiratory 
mortality in the region. Third, HIV infection and tuberculosis are important factors in severe 
respiratory disease in Africa.
The low number of deaths among pregnant women is unexpected, given their increased risk 
of influenza-associated death during the pandemic [12, 21] and increased risk of severe 
disease from seasonal influenza [22], and it may reflect inadequate surveillance in antenatal 
clinics and maternity wards. Owing to high fertility rates, >9% of African women of 
childbearing age are estimated to be pregnant at any given time [23], suggesting that current 
surveillance may not adequately identify severe disease in pregnant women.
From the data collected here nearly two thirds of enrolled SARI cases were children 0–4 
years of age, while adults aged ≥65 years accounted for just 2.4% of SARI cases. Some but 
not all of this difference may be explained by population demographic characteristics in 
Africa; >40% of the population of Africa in 2013 is <15 years of age, and just 3.4% are aged 
≥65 years [24]. There may be differences in access to care among elderly persons in Africa 
that result in fewer elderly individuals with respiratory illness being hospitalized. Our 
analysis demonstrates that elderly persons who are hospitalized have a greater risk of death 
from respiratory disease, especially influenza, than young children. A systematic review of 
the case-fatality risk from the 2009 A(H1N1) pandemic found significant variation in risk by 
age group, ranging from approximately 1 death per 100 000 symptomatic cases in children 
aged 0–19 years to approximately 1000 deaths per 100 000 symptomatic cases in persons 
aged ≥65 years [25]. These estimates support our finding of an increased CFP among 
hospitalized elderly individuals, although only 15.8% of the influenza-associated deaths 
reported here involved influenza A(H1N1) infections (Table 1). Despite this, children aged 
0–4 years accounted for over one third of all SARI-associated deaths and one-third of 
influenza-associated deaths due to SARI in this analysis, a finding consistent with prior 
studies in low-income settings [3, 26]. Likewise, adults aged 18–49 years accounted for over 
one third of all SARI-associated deaths and one third of influenza-associated deaths due to 
SARI, which may be explained by the high prevalence of HIV in this age group.
In this analysis, HIV status was not reported for nearly half of enrolled SARI-associated 
deaths. Despite this limitation, these data clearly demonstrate that HIV infection is common 
among SARI-associated hospitalizations and deaths with and without influenza virus 
coinfection; however, we are unable to demonstrate a statistical association of HIV infection 
with death among hospitalized SARI cases. Our coauthors from South Africa have found 
that HIV-infected patients with influenza were 4 times more likely (95% CI, 1–12) to die 
than HIV-uninfected patients with influenza [2]. Data on tuberculosis were also missing 
from many deaths; however, when reported, tuberculosis was common among SARI-
associated deaths but was not found more commonly among SARI-associated deaths with 
influenza.
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There were several important limitations of this analysis. Because almost 90% of all deaths 
were reported from Kenya and South Africa, our findings may not be representative. In 
South Africa, a country with systematic reporting and a relatively high CFP in this analysis, 
retrospective review of respiratory deaths in sentinel hospitals found that as many as 1 in 3 
respiratory deaths were not enrolled in SARI surveillance [27]. Some countries in our study 
reported very few or no SARI-associated deaths, which limits confidence in conclusions 
drawn from these data. Also, substantial differences existed in how SARI, HIV status, M. 
tuberculosis coinfection, and other underlying medical conditions were diagnosed or defined 
for surveillance purposes. It is likely that very severely ill patients would not have been 
enrolled into surveillance, especially if informed consent was required, as was the case in 
several countries. This may explain why 149 of 1222 reported deaths (12%) did not have 
influenza virus test results. Another limitation is the ability to attribute death to any one 
pathogen. Although influenza viruses are less commonly found in asymptomatic persons, 
other viruses, such as rhinoviruses and adenoviruses, are frequently isolated from 
nasopharyngeal or oropharyngeal swab specimens in asymptomatic persons, especially 
children [28–31]. The relative contribution of these pathogens to mortality may also be 
affected. Nasopharyngeal or oropharyngeal swab specimens may not be the ideal specimens 
for detecting some respiratory pathogens [32]. Also, the methods of testing for some non–
influenza virus pathogens differed by site. For example, South Africa diagnosed S. 
pneumoniae infection on the basis of lytA PCR of blood samples, while Kenya used blood 
cultures to diagnose invasive S. pneumoniae infection. Our study is limited in its ability to 
assess the true role of pathogens other than influenza virus since data on the number of cases 
tested for each pathogen were not available.
Sentinel surveillance sites are often limited in their population catchment and may not 
capture an adequate number of respiratory disease– and influenza-associated deaths. 
Because of the logistics of specimen collection, transport, and analysis, many countries are 
only able to support a small number of sites, which may not be representative of the 
population. Limited access to care in many African settings may further reduce the number 
of persons hospitalized with respiratory infections, including influenza. Many cases of SARI 
may be due to secondary complications such as bacterial pneumonia after initial influenza 
virus infection, when influenza virus shedding has decreased or ceased. Moreover, 
influenza-associated deaths with a nonrespiratory presentation, including heart attack and 
stroke, are unlikely to be tested for influenza virus even if hospitalized. Many complications 
of influenza, especially postinfluenza pneumonia and death, happen >1 week after initial 
infection [33, 34] and therefore may occur at home after discharge. Vital registration data in 
South Africa indicate that as many as 50% of respiratory disease–associated deaths occur 
outside of hospitals [35].
Because of these limitations many countries have used other methods to estimate influenza-
associated mortality. Some sites have conducted thorough community-based mortality 
reviews in which persons meeting the case definition of influenza-associated death are 
counted in a defined population [36, 37]. Excess mortality modeling is commonly used to 
assess deaths due to influenza in populations with accurate vital statistics or International 
Classification of Diseases–coded hospitalization data, with or without adjustment for 
influenza virus circulation [6, 38, 39]; however, few countries in Africa have complete vital 
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registration data, and many countries do not experience clear seasonal peaks in influenza 
transmission, which may limit the utility of such methods. Many countries in Africa have 
health and demographic surveillance sites where all births and deaths are recorded and 
where deaths are assessed by verbal autopsy. It is possible that an assessment of trends in 
mortality at these sites, combined with virological data on influenza virus circulation 
patterns, may provide more-accurate estimates of influenza-associated deaths when vital 
statistics are not available.
In conclusion, stronger surveillance for respiratory deaths may help to identify risk groups 
for targeted vaccine use and other prevention strategies. Among those tested, respiratory 
viruses other than influenza virus and S. pneumoniae were commonly identified in SARI-
associated deaths of all ages; however, nasopharyngeal carriage may overestimate mortality 
from some of these pathogens. Surveillance in antenatal clinics and/or maternity wards 
should be strengthened to better capture pregnant women, given the WHO’s recent decision 
to prioritize them for influenza vaccination [40]. Sentinel surveillance may provide some 
information on characteristics of influenza-associated deaths but will likely underestimate 
influenza-associated mortality. Alternative methods should be used to estimate influenza-
associated mortality in Africa, depending on the availability of vital statistics, accurate 
hospitalization data, and other forms of demographic and health surveillance.
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Table 3
Respiratory Pathogens Observed Among 834 Deaths Due to Severe Acute Respiratory Illness Detected by 












  Any 247 14 233
  Adenovirus 32 (13.0) 1 (7.1) 31 (13.3)
  Parainfluenza virus 3 13 (5.3) 0 (0) 13 (5.6)
  Respiratory syncytial virus 33 (13.4) 2 (14.3) 31 (13.3)
  Rhinovirus 35 (14.2) 0 (0) 35 (15.0)
  S. pneumoniae 9 (3.6) 0 (0) 9 (3.9)
  Othera 23 (9.3) 0 (0) 23 (9.9)
  None 116 (47.0) 11 (78.6) 105 (45.1)b
≥5 y
  Any 587 37 550
  Adenovirus 32 (5.5) 5 (13.5) 27 (4.9)c
  Parainfluenza virus 3 11 (1.9) 0 (0) 11 (2.0)
  Respiratory syncytial virus 27 (4.6) 1 (2.7) 26 (4.7)
  Rhinovirus 72 (12.3) 4 (10.8) 68 (12.4)
  S. pneumoniae 48 (8.2) 5 (13.5) 43 (7.8)
  Otherd 19 (3.2) 0 (0) 19 (3.5)
  None 381 (64.9) 23 (62.2) 358 (65.1)
Abbreviation: S. pneumoniae, Streptococcus pneumoniae.
a
Bocavirus (n = 1), coronavirus (n = 2), enterovirus (n = 4), human metapneumovirus (n = 8), and parainfluenza viruses (1, 2, and not subtyped; n = 
8).
b
P = .014, by the Fisher exact test.
c
P = .04, by the Fisher exact test.
d
Bocavirus (n = 1), enterovirus (n = 7), human metapneumovirus (n = 5), and parainfluenza viruses (1, 2, and not subtyped; n = 6).
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